MCID: NRV006
MIFTS: 61

Nervous System Cancer

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Nervous System Cancer

MalaCards integrated aliases for Nervous System Cancer:

Name: Nervous System Cancer 12 14
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm 69
Malignant Neoplasm of Nervous System 12
Neoplasm of the Nervous System 28
Tumor of the Nervous System 12
Neoplasm of Nervous System 12
Nervous System Neoplasms 69
Nervous System Neoplasm 12
Neoplasms, Nerve Tissue 41
Nervous System--Cancer 69
Nervous System Tumor 51
Neural Neoplasm 12
Neural Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3093
ICD9CM 34 192 192.9
MeSH 41 D009380
NCIt 46 C35562
SNOMED-CT 64 188306000

Summaries for Nervous System Cancer

Disease Ontology : 12 An organ system cancer located in the nervous system that affects the central or peripheral nervous system.

MalaCards based summary : Nervous System Cancer, also known as neuroepithelial, perineurial, and schwann cell neoplasm, is related to meningioma, familial and ewing sarcoma. An important gene associated with Nervous System Cancer is NF1 (Neurofibromin 1), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Hydrocortisone and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include the nervous system, brain and pituitary, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Nervous System Cancer

Diseases related to Nervous System Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 169)
# Related Disease Score Top Affiliating Genes
1 meningioma, familial 32.1 CDKN2B NF1 NF2 TP53
2 ewing sarcoma 31.7 CASP3 CCND1 CDKN2A ENO2 MYC MYCN
3 peripheral nervous system neoplasm 31.5 BACE1 CASP3 ENO2 MYC MYCN NF1
4 sensory system cancer 31.3 CCND1 CDK2 CDK4 CDKN1A CDKN2A MYC
5 astrocytoma 30.1 CCND1 CDK4 CDKN2A CDKN2B NF1 TP53
6 medulloblastoma 30.1 CASP3 CDKN2B ENO2 MYC MYCN TP53
7 neuroblastoma 30.1 BACE1 CASP3 ENO2 MYC MYCN TP53
8 olfactory neural tumor 12.0
9 ependymoma 11.1
10 mismatch repair cancer syndrome 11.0
11 rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome 10.9
12 neurilemmomatosis 10.8
13 brain cancer 10.8
14 spinal cancer 10.8
15 non-hereditary retinoblastoma 10.8 MYCN RB1
16 neurofibromatosis, familial spinal 10.8 NF1 NF2
17 gliofibroma 10.7 NF1 TP53
18 ring chromosome 7 10.7 CDK4 TP53
19 bilateral retinoblastoma 10.7 MYCN RB1 RBL1
20 plexiform schwannoma 10.7 ENO2 NF1 NF2
21 brain stem astrocytic neoplasm 10.7 CDKN2A TP53
22 amyloid tumor 10.7 NF1 NF2 TUBB3
23 thyroid lymphoma 10.7 CDKN2A CDKN2B TP53
24 cerebral convexity meningioma 10.7 NF2 TP53
25 scrotal carcinoma 10.7 CDKN2A CDKN2B TP53
26 spinal canal and spinal cord meningioma 10.7 ENO2 NF1 NF2
27 breast papillomatosis 10.7 CCND1 CDKN2A
28 spinal meningioma 10.7 ENO2 NF1 NF2
29 dedifferentiated liposarcoma 10.7 CDK4 CDKN2A TP53
30 periosteal chondrosarcoma 10.7 CDK4 CDKN2A RB1
31 lung meningioma 10.7 ENO2 NF2
32 short-rib thoracic dysplasia 4 with or without polydactyly 10.7 CASP3 TP53
33 clear cell ependymoma 10.7 ENO2 NF2 TP53
34 balanitis xerotica obliterans 10.7 CCND1 CDKN2A TP53
35 optic nerve glioma 10.7 ENO2 NF1 TP53
36 askin's tumor 10.7 ENO2 MYC MYCN
37 atypical neurofibroma 10.7 CDKN2A CDKN2B NF1 NF2
38 neurofibroma 10.7 CDKN2A NF1 NF2
39 neurilemmoma 10.7 ENO2 NF1 NF2
40 ischemic fasciitis 10.7 CCND1 CDK4 CDKN2A
41 small cell neuroendocrine carcinoma 10.6 CDKN2A ENO2 TP53
42 atypical follicular adenoma 10.6 CDKN1A ENO2 TP53
43 liver angiosarcoma 10.6 CDK4 ENO2 TP53
44 megaesophagus 10.6 CDKN2A MYC TP53
45 meningeal melanomatosis 10.6 CDKN2A ENO2 TP53
46 squamous cell carcinoma of the oropharynx 10.6 CDKN2A TP53
47 cellular schwannoma 10.6 CDKN2A NF1 NF2 TP53
48 nodular ganglioneuroblastoma 10.6 CDKN1A ENO2 MYCN
49 tongue squamous cell carcinoma 10.6 CASP3 CDKN2A TP53
50 cervix small cell carcinoma 10.6 CDKN2A ENO2 TP53

Graphical network of the top 20 diseases related to Nervous System Cancer:



Diseases related to Nervous System Cancer

Symptoms & Phenotypes for Nervous System Cancer

GenomeRNAi Phenotypes related to Nervous System Cancer according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.8 CASP3 CDK2 CDKN1A CDKN2A RB1 TP53
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.8 CASP3 CCND1 CDK2 CDKN1A CDKN2A MYC
3 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 CDK2 CDK4 ENO2 MYCN RBL1

MGI Mouse Phenotypes related to Nervous System Cancer:

43 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.58 TUBB3 TP53 RBL1 CDK2 BACE1 CCND1
2 behavior/neurological MP:0005386 10.51 TP53 RBL1 CASP3 BACE1 CCND1 CDK4
3 growth/size/body region MP:0005378 10.49 TP53 RBL1 CASP3 BACE1 CCND1 CDK4
4 homeostasis/metabolism MP:0005376 10.47 TP53 RBL1 CCND1 CASP3 BACE1 BCHE
5 mortality/aging MP:0010768 10.46 TUBB3 TP53 RBL1 BACE1 CCND1 BCHE
6 hematopoietic system MP:0005397 10.42 TP53 RBL1 CCND1 CASP3 CDKN1A CDK4
7 cardiovascular system MP:0005385 10.41 RBL1 TP53 CCND1 CASP3 CDKN1A CDK4
8 endocrine/exocrine gland MP:0005379 10.41 TP53 RBL1 CASP3 CCND1 CDK4 CDK2
9 integument MP:0010771 10.39 TP53 RBL1 BACE1 CCND1 CASP3 CDK2
10 embryo MP:0005380 10.38 TP53 RBL1 CDKN1A CDK4 CDK2 CDKN2A
11 immune system MP:0005387 10.37 TP53 RBL1 CCND1 CASP3 CDK4 CDK2
12 craniofacial MP:0005382 10.36 TP53 RBL1 CASP3 CCND1 CDKN1A MYC
13 nervous system MP:0003631 10.36 TP53 RBL1 BACE1 CCND1 CASP3 TUBB3
14 digestive/alimentary MP:0005381 10.35 TP53 RBL1 CASP3 CCND1 CDKN1A CDK4
15 neoplasm MP:0002006 10.29 TP53 RBL1 CDK2 CCND1 CDKN1A CDK4
16 muscle MP:0005369 10.27 TP53 RBL1 CASP3 BACE1 CDK2 CDKN1A
17 liver/biliary system MP:0005370 10.26 TP53 RBL1 CDK4 CDK2 CDKN1A MYC
18 hearing/vestibular/ear MP:0005377 10.24 TP53 RBL1 CASP3 CDKN1A MYC NF1
19 no phenotypic analysis MP:0003012 10.13 TP53 RBL1 CASP3 BACE1 CDKN1A CDKN2B
20 reproductive system MP:0005389 10.13 TP53 RBL1 CCND1 BCHE CASP3 CDK2
21 normal MP:0002873 10.1 TP53 RBL1 CCND1 BACE1 CDK4 MYCN
22 limbs/digits/tail MP:0005371 10.08 TP53 RBL1 RB1 CDKN1A MYCN MYC
23 renal/urinary system MP:0005367 10.02 TP53 RBL1 CASP3 CDKN1A CDK4 CDKN2B
24 respiratory system MP:0005388 9.93 TP53 RBL1 CCND1 CASP3 TUBB3 CDKN1A
25 pigmentation MP:0001186 9.91 TP53 CASP3 CDK4 CDKN2A NF1 MYC
26 skeleton MP:0005390 9.7 TP53 RBL1 CCND1 CASP3 CDKN2A CDKN1A
27 vision/eye MP:0005391 9.4 TP53 RBL1 CASP3 CCND1 CDK4 CDK2

Drugs & Therapeutics for Nervous System Cancer

Drugs for Nervous System Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 682)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 657311 5754
2
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
3
Menthol Approved Phase 4,Phase 1,Phase 2,Early Phase 1 2216-51-5 16666
4
Dacarbazine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 4342-03-4 5351166
5
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
6
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
7
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
8
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3 76631-46-4, 113775-47-6 5311068 56032 68602
9
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 1 28523-86-6 5206
10
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 2078-54-8 4943
11
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
12
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83150-76-9 6400441 383414
13
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
14
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 1 38396-39-3, 2180-92-9 2474
15
Thrombin Approved, Investigational Phase 4
16
Remifentanil Approved Phase 4,Phase 3 132875-61-7 60815
17
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
18
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
19
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
20
Ibuprofen Approved Phase 4 15687-27-1 3672
21
Morphine Approved, Investigational Phase 4,Phase 2 57-27-2 5288826
22
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
23
Clevidipine Approved, Investigational Phase 4 167221-71-8
24
Hydralazine Approved Phase 4 86-54-4 3637
25
Labetalol Approved Phase 4 36894-69-6 3869
26
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
27
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2 20748-11-2, 113-45-1 4158
28 Piracetam Approved, Investigational Phase 4,Phase 2 7491-74-9
29
Mitoxantrone Approved, Investigational Phase 4,Phase 1 65271-80-9 4212
30
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
31
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 38916-34-6, 51110-01-1 53481605
32
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
33
Cefazolin Approved Phase 4 25953-19-9 33255 656510
34
Cefdinir Approved Phase 4 91832-40-5 6915944
35
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
36
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
37
Sulfamethoxazole Approved Phase 4,Phase 1 723-46-6 5329
38
Trimethoprim Approved, Vet_approved Phase 4,Phase 1 738-70-5 5578
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
40
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 143 6006
41
Glutamic Acid Approved, Nutraceutical Phase 4,Phase 1 56-86-0 33032
42
Butyric Acid Experimental, Investigational Phase 4,Phase 2 107-92-6 264
43 Etiracetam Investigational Phase 4,Phase 1,Phase 2 33996-58-6
44
Lactitol Investigational Phase 4,Phase 2 585-86-4 3871
45 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
46 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
48 Cortisol succinate Phase 4,Phase 2
49 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
50 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1773)

# Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 Characterization of Receptors in Non-functioning Pituitary Macroadenomas Unknown status NCT00852501 Phase 4
3 Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System Completed NCT02343081 Phase 4 Temozolomide;Temozolomide
4 Validation of 3 Dimensional Laparoscopic System in Disral Pancreatectomy and Splenectomy Completed NCT02757690 Phase 4
5 DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor Completed NCT00029523 Phase 4 Intrathecal (injected into the spinal fluid) DepoCyt;Intrathecal methotrexate;Intrathecal cytarabine (also known as ara-C)
6 Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy Completed NCT02810899 Phase 4 dexmedetomidine;normal saline
7 Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants Completed NCT02708056 Phase 4 Sugammadex
8 Scalp Nerve Block and Opioid Consumption in Brain Surgery Completed NCT02057367 Phase 4 Scalp block with 0.5% plain Marcaine;Scalp block with 0.9% normal saline
9 Phase IV Bioseal Study in Brain Tumor Surgery Completed NCT02034799 Phase 4
10 Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors Completed NCT02034708 Phase 4 Dotarem®;Gadovist®/Gadavist®
11 Remifentanil Infusion Alone During the Closure Period for Early Emergence Following Craniotomy Completed NCT02593942 Phase 4 Remifentanil;Propofol
12 Multihance at 3 Tesla in Brain Tumors Completed NCT00395863 Phase 4 Multihance;Arm 2 - Magnevist
13 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
14 Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
15 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
16 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
17 Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors Completed NCT00075166 Phase 4
18 A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients Completed NCT00952081 Phase 4 Clevidipine
19 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
20 Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery Completed NCT00571155 Phase 4 levetiracetam
21 Effect of 5 Years of GH Replacement on Atherosclerosis Completed NCT00462475 Phase 4 Recombinant Growth Hormone, Genotropin (Pfizer)
22 NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate Completed NCT00169611 Phase 4 methylphenidate
23 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
24 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
25 Single Dose Tramadol Effect on Extubation Response and Quality of Emergence Post-supratentorial Intracranial Surgery Recruiting NCT02964416 Phase 4 Injection Tramadol
26 Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach Recruiting NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
27 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
28 Cavernous Sinus Dissection and Bleeding in Meningiomas Recruiting NCT02863484 Phase 4
29 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Recruiting NCT02478346 Phase 4 Fluorescein Sodium
30 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Recruiting NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
31 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
32 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4 Gentamicins
33 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
34 Comparison of Efficacy and Safety of the Postoperative Analgesia Methods Not yet recruiting NCT02929147 Phase 4 Morphine;Dexketoprofen;Placebo
35 Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. Not yet recruiting NCT03190122 Phase 4
36 Different Dose of Methotrexate for the Treatment of Meningeal Carcinomatosis Not yet recruiting NCT02590510 Phase 4 methotrexate
37 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Terminated NCT02028325 Phase 4 Fluorescein Sodium
38 Treatment of Resectable Malignant Brain Tumors Terminated NCT00415467 Phase 4
39 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
40 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
41 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
42 Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
43 Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma Unknown status NCT00053872 Phase 3 cisplatin;lomustine;vincristine sulfate
44 Quality of Life in Patients Who Have Undergone Previous Treatment for Primitive Neuroectodermal Tumors Unknown status NCT00278239 Phase 3
45 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
46 Prevention of Imminent Paralysis Following Spinal Cord Trauma or Ischemia by Minocycline: A Multi-center Study in Israel With IDF Primary Care Involvement Unknown status NCT01813240 Phase 2, Phase 3 Minocycline;placebo
47 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
48 Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children Unknown status NCT00749723 Phase 2, Phase 3 carboplatin;etoposide;temozolomide;thiotepa, carboplatin, etoposide;temozolomide, thiotepa;etoposide;trofosfamide/etoposide
49 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
50 Stereotactic Radiotherapy of Resection Cavity For Single Brain Metastasis Versus Whole-Brain Radiotherapy After Resection Unknown status NCT01535209 Phase 3

Search NIH Clinical Center for Nervous System Cancer

Cochrane evidence based reviews: neoplasms, nerve tissue

Genetic Tests for Nervous System Cancer

Genetic tests related to Nervous System Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of the Nervous System 28

Anatomical Context for Nervous System Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Nervous System Cancer:

18
The Nervous System

MalaCards organs/tissues related to Nervous System Cancer:

38
Brain, Pituitary, Lung, Breast, Bone, Bone Marrow, T Cells

Publications for Nervous System Cancer

Articles related to Nervous System Cancer:

(show all 25)
# Title Authors Year
1
Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review. ( 29374660 )
2018
2
The Complex Diagnostic Challenge in Children With Non-Central Nervous System Cancer and Cerebellar Mutism. ( 28497710 )
2017
3
Meta-Analysis of the Effects of Neuropsychological Interventions on Cognitive Function in Non-Central Nervous System Cancer Survivors. ( 27151596 )
2016
4
Brain and central nervous system cancer incidence in navarre (Spain), 1973-2008 and projections for 2014. ( 25561983 )
2015
5
Stat Bite Number of New Brain and Other Nervous System Cancer Cases By Race/Ethnicity & Sex (2008-2012). ( 26538626 )
2015
6
Five-year relative survival rate of brain and other nervous system cancer in the USA, Europe and Japan. ( 25717112 )
2015
7
Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. ( 25483452 )
2015
8
Identification of miRNAs as potential new biomarkers for nervous system cancer. ( 25139093 )
2014
9
Vocational identity, positive affect, and career thoughts in a group of young adult central nervous system cancer survivors. ( 25035908 )
2014
10
Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients. ( 23661397 )
2013
11
Comparison of time trends in brain and central nervous system cancer mortality (1990-2006) between countries based on the WHO mortality database. ( 21273379 )
2011
12
Medulloblastoma and Brucellosis - Molecular Evidence of Brucella sp in Association with Central Nervous System Cancer. ( 21475718 )
2011
13
Long-term health experience of jet engine manufacturing workers: IV. A comparison of central nervous system cancer ascertainment using mortality and incidence data. ( 20816315 )
2010
14
Pain in children with central nervous system cancer: a review of the literature. ( 20591796 )
2010
15
Induction of cytotoxicity, apoptosis and cell cycle arrest by 1-t-butyl carbamoyl, 7-methyl-indole-3-ethyl isothiocyanate (NB7M) in nervous system cancer cells. ( 19920894 )
2009
16
School-aged children after the end of successful treatment of non-central nervous system cancer: longitudinal assessment of health-related quality of life, anxiety and coping. ( 19594611 )
2009
17
Molecular predictors of human nervous system cancer responsiveness to enediyne chemotherapy. ( 18338171 )
2008
18
Comparison of time trends in brain central nervous system cancer incidence (1973-97) in East Asia, Europe and USA, from Cancer Incidence in Five Continents Vols IV-VIII. ( 18772173 )
2008
19
Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. ( 18415683 )
2008
20
Cytotoxicity and oncostatic activity of the thiazolidinedione derivative CGP 52608 on central nervous system cancer cells. ( 15194216 )
2004
21
Exploitation of immune mechanisms in the treatment of central nervous system cancer. ( 10914414 )
2000
22
Nervous system cancer mortality in an industrialized area of Brazil 1980-1993. ( 10920400 )
2000
23
Risk of nervous system cancer among workers exposed to lead. ( 8673517 )
1996
24
Human malignant astrocytoma xenografts migrate in rat brain: a model for central nervous system cancer research. ( 2651679 )
1989
25
Brain and central nervous system cancer mortality in U. S. rubber workers. ( 6953785 )
1982

Variations for Nervous System Cancer

Expression for Nervous System Cancer

Search GEO for disease gene expression data for Nervous System Cancer.

Pathways for Nervous System Cancer

Pathways related to Nervous System Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 82)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 CASP3 CCND1 CDK2 CDK4 CDKN1A CDKN2A
2
Show member pathways
13.8 CCND1 CDK2 CDK4 CDKN1A CDKN2A CDKN2B
3
Show member pathways
13.55 CCND1 CDK2 CDK4 CDKN1A CDKN2A CDKN2B
4
Show member pathways
13.22 CDK2 CDK4 CDKN1A CDKN2A CDKN2B RB1
5
Show member pathways
13.18 CASP3 CCND1 CDK2 CDK4 CDKN1A CDKN2A
6
Show member pathways
13.14 CASP3 CCND1 CDK2 CDK4 CDKN1A MYC
7 12.97 CASP3 CCND1 CDK2 CDK4 CDKN1A CDKN2A
8
Show member pathways
12.92 CCND1 CDK2 CDK4 CDKN1A CDKN2A CDKN2B
9
Show member pathways
12.86 CASP3 CDKN1A CDKN2A MYC TP53
10
Show member pathways
12.84 CASP3 CCND1 CDK2 CDK4 TP53
11
Show member pathways
12.84 CCND1 CDK2 CDK4 CDKN1A MYC RB1
12
Show member pathways
12.75 CASP3 CCND1 CDK2 CDK4 CDKN1A MYC
13 12.72 BACE1 ENO2 MYCN NF1 NF2 TUBB3
14
Show member pathways
12.7 CCND1 CDK4 CDKN1A CDKN2A RB1 TP53
15 12.69 CCND1 CDK2 CDK4 CDKN1A CDKN2A RB1
16 12.65 CASP3 CCND1 CDKN1A CDKN2A MYC TP53
17
Show member pathways
12.62 CCND1 CDK2 CDK4 CDKN1A CDKN2A CDKN2B
18 12.61 CCND1 CDK2 CDK4 MYC RB1 RBL1
19 12.58 CCND1 CDK4 CDKN1A CDKN2A CDKN2B MYC
20
Show member pathways
12.47 CASP3 CCND1 CDK2 CDK4 CDKN1A CDKN2A
21
Show member pathways
12.46 CCND1 CDK2 CDK4 RB1
22
Show member pathways
12.44 CCND1 CDKN1A MYC TP53
23
Show member pathways
12.44 CCND1 CDK2 CDK4 CDKN1A CDKN2A CDKN2B
24 12.43 CDK2 CDKN1A MYC RB1 TP53
25
Show member pathways
12.43 CASP3 CCND1 CDK2 CDK4 CDKN1A RB1
26 12.43 CCND1 CDK2 CDK4 CDKN1A CDKN2A CDKN2B
27 12.42 CASP3 CCND1 CDKN1A MYC TP53
28
Show member pathways
12.4 CDK2 CDKN1A RB1 TP53
29
Show member pathways
12.39 CASP3 CCND1 CDK2 CDK4 CDKN1A MYC
30
Show member pathways
12.37 CCND1 CDK2 CDK4 CDKN1A CDKN2A CDKN2B
31 12.32 CASP3 CCND1 CDKN1A MYC TP53
32 12.32 CASP3 CCND1 CDK2 CDK4 CDKN1A CDKN2A
33 12.31 CDKN1A MYC MYCN TP53
34
Show member pathways
12.31 CCND1 CDK4 CDKN1A CDKN2A MYC RB1
35 12.28 CASP3 CCND1 CDK2 CDK4 MYC NF1
36 12.26 CCND1 CDKN1A CDKN2B MYC RBL1 TP53
37 12.25 CCND1 CDK2 CDK4 CDKN1A CDKN2A TP53
38 12.19 CDK2 CDKN1A CDKN2A RB1 TP53
39 12.19 CASP3 CCND1 CDK2 CDK4 MYC RB1
40
Show member pathways
12.17 CCND1 CDK2 CDKN1A CDKN2B
41 12.16 CCND1 CDK2 CDK4 CDKN1A CDKN2A CDKN2B
42
Show member pathways
12.15 CCND1 CDK2 CDK4 NF1
43 12.15 CCND1 CDKN1A CDKN2A MYC TP53
44 12.09 CCND1 CDKN1A MYC TP53
45 12.05 CDKN1A CDKN2A RB1 TP53
46
Show member pathways
12.03 CDK2 CDKN1A RBL1 TP53
47 12 CCND1 CDK2 CDK4 CDKN1A MYC RB1
48
Show member pathways
11.98 CCND1 CDK2 CDK4 RB1 RBL1
49 11.96 CDK2 CDK4 CDKN1A CDKN2B MYC RBL1
50 11.94 CDK2 CDKN1A MYC RB1 RBL1

GO Terms for Nervous System Cancer

Cellular components related to Nervous System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin GO:0000785 9.56 CDK4 MYCN RB1 TP53
2 nucleolus GO:0005730 9.56 CDK4 CDKN1A CDKN2A MYC MYCN NF1
3 transcription factor complex GO:0005667 9.55 CDK2 CDK4 RB1 RBL1 TP53
4 cyclin-dependent protein kinase holoenzyme complex GO:0000307 8.92 CCND1 CDK2 CDK4 CDKN1A
5 nucleus GO:0005634 10.2 CASP3 CCND1 CDK2 CDK4 CDKN1A CDKN2A

Biological processes related to Nervous System Cancer according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.98 BCHE CASP3 CCND1 CDK4 CDKN1A MYC
2 negative regulation of gene expression GO:0010629 9.97 CDKN1A MYC MYCN RB1 RBL1
3 negative regulation of cell proliferation GO:0008285 9.92 BCHE CDKN1A CDKN2A CDKN2B NF1 NF2
4 response to organic cyclic compound GO:0014070 9.91 CASP3 CCND1 CDKN1A TP53
5 cell cycle GO:0007049 9.91 CCND1 CDK2 CDK4 CDKN1A CDKN2A CDKN2B
6 negative regulation of protein kinase activity GO:0006469 9.89 CDKN2A NF1 NF2 RB1
7 regulation of mitotic cell cycle GO:0007346 9.86 CDKN1A MYC RB1
8 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.85 CDK2 CDKN1A TP53
9 response to organic substance GO:0010033 9.85 CASP3 CCND1 CDK2 CDK4 CDKN1A
10 cell cycle arrest GO:0007050 9.85 CDKN1A CDKN2A CDKN2B MYC RB1 TP53
11 positive regulation of fibroblast proliferation GO:0048146 9.84 CDK4 CDKN1A MYC
12 response to UV GO:0009411 9.83 CASP3 CDKN1A TP53
13 positive regulation of neuron apoptotic process GO:0043525 9.83 CASP3 NF1 TP53
14 response to glucocorticoid GO:0051384 9.83 BCHE CASP3 CCND1 CDKN1A
15 animal organ regeneration GO:0031100 9.81 CCND1 CDK4 CDKN1A
16 cellular response to heat GO:0034605 9.8 CDKN1A NF1 TP53
17 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.8 CDKN1A CDKN2B RB1
18 response to organonitrogen compound GO:0010243 9.78 CCND1 CDKN1A TP53
19 positive regulation of cell cycle GO:0045787 9.78 CCND1 CDK4 MYC TP53
20 negative regulation of fibroblast proliferation GO:0048147 9.77 MYC NF1 TP53
21 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.75 CASP3 CDKN1A CDKN2A
22 negative regulation of phosphorylation GO:0042326 9.73 CDKN1A CDKN2A CDKN2B
23 response to hyperoxia GO:0055093 9.72 CDK4 CDKN1A TP53
24 negative regulation of cell-matrix adhesion GO:0001953 9.71 CDKN2A NF1 NF2
25 response to X-ray GO:0010165 9.71 CASP3 CCND1 CDKN1A TP53
26 replicative senescence GO:0090399 9.69 CDKN1A CDKN2A TP53
27 negative regulation of astrocyte differentiation GO:0048712 9.68 MYCN NF1
28 cellular response to phorbol 13-acetate 12-myristate GO:1904628 9.68 CDK4 MYC
29 re-entry into mitotic cell cycle GO:0000320 9.67 CCND1 MYC
30 mitotic G1 DNA damage checkpoint GO:0031571 9.67 CCND1 CDK2 TP53
31 signal transduction by p53 class mediator GO:0072331 9.65 CDKN1A TP53
32 regulation of lipid kinase activity GO:0043550 9.64 RB1 RBL1
33 Ras protein signal transduction GO:0007265 9.63 CDK2 CDKN1A CDKN2A NF1 RB1 TP53
34 glial cell apoptotic process GO:0034349 9.62 CASP3 RB1
35 regulation of cell cycle GO:0051726 9.5 CCND1 CDK2 CDK4 CDKN1A NF2 RB1
36 G1/S transition of mitotic cell cycle GO:0000082 9.17 CCND1 CDK2 CDK4 CDKN1A CDKN2A MYC
37 positive regulation of transcription by RNA polymerase II GO:0045944 10.21 CDKN2A CDKN2B MYC MYCN RB1 RBL1
38 negative regulation of transcription by RNA polymerase II GO:0000122 10.16 CCND1 CDK2 MYC RB1 RBL1 TP53
39 positive regulation of transcription, DNA-templated GO:0045893 10.11 CDK2 CDKN2A MYC MYCN RB1 TP53
40 positive regulation of cell proliferation GO:0008284 10.09 CCND1 CDK2 CDK4 MYC MYCN
41 cellular response to DNA damage stimulus GO:0006974 10.06 CASP3 CCND1 CDK2 CDKN1A MYC TP53
42 positive regulation of apoptotic process GO:0043065 10.05 CASP3 CDK4 CDKN2A NF1 TP53

Molecular functions related to Nervous System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.93 CCND1 CDK2 CDK4 CDKN1A CDKN2A CDKN2B
2 protein kinase binding GO:0019901 9.88 CCND1 CDKN1A CDKN2A CDKN2B TP53
3 enzyme binding GO:0019899 9.83 BACE1 BCHE CCND1 RB1 TP53
4 protein complex binding GO:0032403 9.65 CASP3 CCND1 CDK4 CDKN1A MYC
5 transcription factor binding GO:0008134 9.63 CCND1 CDKN2A MYC RB1 RBL1 TP53
6 disordered domain specific binding GO:0097718 9.54 CDKN2A RB1 TP53
7 cyclin binding GO:0030332 9.5 CDK2 CDK4 CDKN1A
8 cyclin-dependent protein serine/threonine kinase activity GO:0004693 9.26 CCND1 CDK2 CDK4 CDKN1A
9 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.92 CASP3 CDKN1A CDKN2A CDKN2B
10 protein binding GO:0005515 10.36 BACE1 CASP3 CCND1 CDK2 CDK4 CDKN1A

Sources for Nervous System Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....